Attention to prevention

Omega-6/3 Fatty Acids: Functions, Sustainability Strategies and Perspectives

Volumn , Issue , 2013, Pages 13-26

  Lands, Bill ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Absenteeism; Atherosclerosis; Cardiovascular; Cholesterol; Food energy; Free fatty acids (FFA); Health care claim; Health risk assessment (HRA); Heart attack; Highly unsaturated fatty acids (HUFA); Hormone; Immune in fl ammatory; Kilocalories (Cal); Metabolic syndrome; Omega 3 6 Balance Scores; Omega 3; Omega 6; Prediction; Presenteeism; Prevention; Psychiatric disorders; Self insured; Symptoms; Thrombosis; Very low density lipoproteins (VLDL)

Indexed keywords

EID: 84901279070     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-215-5_2     Document Type: Chapter

References (43)

1. Lands B. A critique of paradoxes in current advice on dietary lipids. Prog Lipid Res. 2008;47:77-106.
2. Lands B. Planning primary prevention of coronary disease. Curr Atheroscler Rep. 2009;11(4): 272-80.
3. Indiana University-Purdue University, Fort Wayne (IPFW) Study, 2006; http://www.redorbit.com/news/ health/788667/new_ipfw_study_finds_87_of_health_claims_lifestyle_related/. Accessed 30 Sept 2012
4. Health Care Statistics. http://preventdisease.com/worksite_wellness/health_stats.shtml. Accessed 30 Sept 2011.
5. Mayo Clinic report. http://www.mayoclinic.com/health/metabolic%20syndrome/DS00522/ DSECTION=symptoms. Accessed 30 Sept 2012.
6. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol. 1977;86(3):675-84.
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2): 115-26. Review. PubMed PMID: 9887164.
8. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5 Pt 2):S419-20. Review. PubMed PMID: 10539839.
9. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131-6.
10. Lands WEM, Hamazaki T, Yamazaki K, Okuyama H, Sakai K, Goto Y, et al. Changing dietary patterns. Am J Clin Nutr. 1990;51:991-3.
11. Ogushi Y, Hamazaki T, Kirihara Y. Blood cholesterol as a good marker of health in Japan. World Rev. Nutr. Diet. 2009; 100: 63-70.
12. Lands WEM, Pitt B, Culp BR. Recent concepts on platelet function and dietary lipids in coronary thrombosis, vasospasm and angina. Herz. 1980;5:34-41.
13. Lands WEM. Fish and human health. Orlando, FL: Academic; 1986.
14. Omega 3-6 Balance Scores. http://www.fastlearner.org/Omega3-6Balance.htm. Accessed 30 Sept 2011.
15. Lands B, Lamoreaux E. Describing essential fatty acid balance as 3-6 differences rather than 3/6 ratios. Nutrition & Metabolism 2012, 9: 46-54.
16. Mohrhauer H, Holman RT. Effect of linolenic acid upon the metabolism of linoleic acid. J Nutr. 1963;81:67-74.
17. Lands WEM, Libelt B, Morris A, Kramer NC, Prewitt TE, Bowen P, et al. Maintenance of lower proportions of n-6 eicosanoid precursors in phospholipids of human plasma in response to added dietary n-3 fatty acids. Biochim Biophys Acta. 1992;1180:147-62.
18. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem. 2007;282(31):22254-66.
19. Lands B. Measuring blood fatty acids as a surrogate indicator for coronary heart disease. World Rev Nutr Diet. 2009;100:22-34.
20. Lands WE. Diets could prevent many diseases. Lipids. 2003;38(4):317-21.
21. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363-7.
22. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113-8.
23. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr. 2006;83(6 Suppl):1483S-93.
24. Lands B. Prevent the cause, not just the symptoms. Prostaglandins Other Lipid Mediat. 2011;96(1-4):90-3. PubMed PMID: 21827870.
25. Lands B. False profits and silent partners in health care. Nutr Health. 2009;20(2):79-89.
26. Loeppke R, Taitel M, Richling D, Parry T, Kessler RC, Hymel P, et al. Health and productivity as a business strategy. J Occup Environ Med. 2007;49(7):712-21.
27. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control Clin Trials. 2001;22:485-502.
28. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-43.
29. Carey J. Do cholesterol drugs do any good? Available at http://www.businessweek.com/magazine/ content/08_04/b4068052092994.htm. Accessed 30 Sept 2011.
30. Carey J. Heart disease: not about cholesterol? Available at http://www.businessweek.com/bwdaily/dnflash/ content/apr2008/db20080414_688906.htm. Accessed 30 Sept 2011.
31. Couzin J. Cholesterol veers off script. Science. 2008;322:220-3.
32. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part IV: The 1984 coronary primary prevention trial ends it-almost. J Lipid Res. 2006;47(1):1-14.
33. Consensus conference. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253(14): 2080-6.
34. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77(11):1417-26.
35. AHA Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update. Circulation; 2011. Downloaded from http://circ.ahajournals.org/ on 3 Sept 2011.
36. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-28.
37. Hoogwerf BJ. Action to Control Cardiovascular Risk in Diabetes Study Group: does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med. 2008;75:729-37.
38. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-97. PubMed PMID: 19318384.
39. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. JUPITER Study Group: rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
40. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93(5):950-62.
41. Nestle M. Food politics: how the food industry influences nutrition and health. Berkeley: University of California Press; 2007.
42. Imhoff D. Foodfight: the citizen's guide to a food and farm bill. Healdsburg, CA: Watershed Media; 2007.
43. Simon M. Appetite for profit: how the food industry undermines our health and how to fight back. New York: Nation Books; 2006.